STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 March 2004 please refer to module 8B 
• 
• 
• 
• 
• 
• 
• 
• 
On  7  March  2000  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of  this  variation  was  to  make  a  minor  change  in  the  manufacturing  process  of  the  active 
substance.  The  procedure  started  on  13  March  2000.  The  EMEA  notified  the  European 
Commission  on  10  April  2000  that  the  variation  was  accepted  and  did  not  require  any 
amendment to the Community Marketing Authorisation. 
On 21 June 2000, the MAH submitted an application for a type II variation in accordance with 
Article 6 of Commission Regulation (EC) 542/95 as amended. The scope of the variation was to 
update  the  SPC  and  PL  based  on  the  5th  PSUR  and  a  separate  review  of  cases  of  diabetic 
ketoacidosis  and  coma.  The  CPMP  adopted  a  positive  Opinion  on  21  September  2000.  The 
respective European Commission Decision was issued on 27 December 2000. 
On 6 December 2000, the MAH submitted an application for a type II variation in accordance 
with Article 6 of Commission Regulation (EC) 542/95 as amended. The scope of the variation 
was  to  update  the  section  4.8  of  the  SPC  regarding  information  on  hyperglycaemia,  and  the 
respective section of the PL to reflect this change. The procedure started on 15 December 2000. 
The CPMP adopted a positive Opinion on 1 March 2001. The respective European Commission 
Decision was issued on 14 June 2001. 
On  3  January  2001  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of  this  variation  was  to  demonstrate  compliance  with  the  Commission  Directive  1999/82/EC 
and  the  Note  for  Guidance  on  Minimising  the  risk  of  transmitting  animal  spongiform 
encephalopathy agents via medicinal products (CPMP/BWP/1230/98). The procedure started on 
5  January  2001.  The  EMEA  notified  the  European  Commission  on  2  February  2001  that  the 
variation was accepted and did not require any amendments to the Commission Decision. 
On 19 February 2001 the MAH submitted to the EMEA an application for a type I variation in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of the variation was to change the address of the MAH. The procedure started on 23 February 
2001. The EMEA notified the European Commission on 1 March 2001 that the variation was 
accepted.  Amendments  to  the  Annexes  I,  IIIA  and  IIIB  were  required  and  the  Commission 
Decision was issued on 14 June 2001. 
On 14 March 2001 the MAH submitted an application for a type II variation in accordance with 
Article  6  of  Commission  Regulation  (EC)  542/95  as  amended.  The  MAH  applied  for  an 
extension of the therapeutic indication to patients with bipolar disorder suffering from a manic 
episode.  The  CPMP  adopted  a  positive  Opinion  on  21  February  2002  for  the  indication 
“olanzapine is indicated for the treatment of a moderate to severe manic episode; olanzapine has 
not been demonstrated to prevent recurrence of manic or depressive episodes”. The respective 
Commission Decision was issued on 4 June 2002. 
On 22 May 2001, the MAH submitted an application for a type II variation in accordance with 
Article 6 of Commission Regulation (EC) 542/95 as amended. The MAH applied for an update 
of the SPC, labelling and PL to maintain consistency of the texts following the 5-year renewal 
application for Zyprexa. The procedure started on 1 June 2001. The CPMP adopted a positive 
Opinion  on  26  July  2001.  The  respective  Commission  Decision  was  issued  on  20  November 
2001. 
On  1  March  2002,  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
procedure started on 15 March 2002. The scope of this variation was to add a new packaging 
site and rename an authorised packaging site. The EMEA notified the European Commission on 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
15  April  2002  that  the  variation  was  accepted  and  did  not  require  any  amendment  to  the 
Community Marketing Authorisation. 
On 12 February 2002, the MAH submitted an application for a type II variation in accordance 
with Article 6 of Commission Regulation (EC) 542/95 as amended. The procedure started on 22 
February  2002.  The  MAH  applied  for  an  update  of  the  SPC  sections  4.8  and  4.5  and  the 
corresponding sections of the PL following the 7th PSUR. The procedure started on 22 February 
2002.  The  CPMP  adopted  a  positive  Opinion  on  30  May  2002.  The  respective  Commission 
Decision was issued on 10 September 2002. 
Pursuant to article 61(3) of Council Directive No. 2001/83/EC of 6 November 2001, the MAH 
notified the EMEA on 26 September 2002 of their intention to introduce changes to an aspect of 
the  PL  not  connected  to  the  SPC.  On  25  October  2002,  the  EMEA  notified  the  European 
Commission that the changes were accepted. 
On  6  December  2002,  the  MAH  submitted  an  application  for  a  type  II  variation  in  accordance 
with Article 6 of Commission Regulation (EC) 542/95 as amended. The procedure started on 20 
December  2002.  The  application  related  to  an  update  in  section  4.1  of  the  SPC  to  extend  the 
therapeutic indication to include prevention of recurrence in  patients with bipolar disorder.  The 
CPMP adopted a positive Opinion on 27 July 2003 for the indication “olanzapine is indicated for 
the  prevention  of  recurrence  in  patients  with  bipolar  disorder”.  The  respective  Commission 
Decision was issued on 24 October 2003. 
On 4 February 2003, the MAH submitted an application for a type II variation in accordance with 
Article  6  of  Commission  Regulation  (EC)  542/95  as  amended.  The  procedure  started  on  24 
February  2003.  The  application  referred  to  an  update  to  section  4.6  of  the  SPC  regarding  the 
levels  of  olanzapine  found  in  breast  milk,  as  well  as  section  4.8  regarding  EPS  following  the 
review of the 9th PSUR. The CPMP adopted a positive Opinion on 26 June 2003. The respective 
Commission Decision was issued on 8 October 2003. 
On  5  March  2003  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope  of  this  variation  was  to  change  the  qualitative  composition  of  the  immediate  packaging 
material.  This  variation  was  accepted  by  the  EMEA  on  7  April  2003  and  did  not  require  any 
amendment to the Community Marketing Authorisation. 
On 15 December 2003, the MAH submitted to the EMEA an application for a type I variation in 
accordance  with  Annex  I  (No.  IB29A)  of  Commission  Regulation  (EC)  No.  1085/2003.  The 
scope  of  this  variation  was  for  an  alternative  composition  of  the  aluminium  blister  and  the  foil 
backing for the aluminium blister. This variation was accepted by the EMEA on 12 January 2004. 
On  4 February 2004, the  MAH  submitted to the EMEA an application for  a type I variation in 
accordance with Annex I (No. IA47a) of Commission Regulation (EC) No. 1085/2003. The scope 
of  this  variation  was  to  change  the  name  of  the  manufacturing,  control  testing  and  primary 
packaging site. This variation was accepted by the EMEA on 9 February 2004. 
On 1 March 2004, an Urgent Safety Restriction procedure was started at the request of the MAH 
to  include  information  on  cerebrovascular  adverse  events  and  increased  mortality  in  elderly 
patients with dementia. The procedure was finalised on 2 March 2004. 
2/2 
EMEA 2005 
 
 
 
 
 
